High expression of PD-L1 in tumor cells and stromal lymphocytes accompanied by low CD8+ T cell infiltration has recently been identified as a poor prognostic biomarker in patients with stage III non-small cell lung cancer (NSCLC) receiving cisplatin-based RCT [45]. Here, CD274 is linked to non-small cell lung carcinoma.